Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - felodipine - tablets extended release - felodipine 10 mg - felodipine - felodipine - moderate to severe hypertension. angina pectoris.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - felodipine - tablets extended release - felodipine 5 mg - felodipine - felodipine - moderade to severe hypertension.angina pectoris.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - felodipine - tablets extended release - felodipine 2.5 mg - felodipine - felodipine - hypertension. angina pectoris.

Israel - English - Ministry of Health

teva israel ltd - caffeine anhydrous; chlorpheniramine maleate; paracetamol; phenylephrine hydrochloride - tablets - paracetamol 300 mg; chlorpheniramine maleate 2.0 mg; phenylephrine hydrochloride 10 mg; caffeine anhydrous 30 mg - phenylephrine, combinations - symptomatic relief of common cold, congestion associated with sinusitis, allergic rhinitis accompanied by fever and pain.

Israel - English - Ministry of Health

novartis israel ltd., israel - cefuroxime as axetil - tablets - cefuroxime as axetil 125 mg - cefuroxime - cefuroxime - zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months .• acute streptococcal tonsillitis and pharyngitis.• acute bacterial sinusitis.• acute otitis media.• acute exacerbations of chronic bronchitis.• cystitis.• pyelonephritis.• uncomplicated skin and soft tissue infections. •treatment of early lyme disease.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

novartis israel ltd., israel - cefuroxime as axetil - tablets - cefuroxime as axetil 250 mg - cefuroxime - cefuroxime - zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months .• acute streptococcal tonsillitis and pharyngitis.• acute bacterial sinusitis.• acute otitis media.• acute exacerbations of chronic bronchitis.• cystitis.• pyelonephritis.• uncomplicated skin and soft tissue infections. •treatment of early lyme disease.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

novartis israel ltd., israel - cefuroxime as axetil - tablets - cefuroxime as axetil 500 mg - cefuroxime - zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months .• acute streptococcal tonsillitis and pharyngitis.• acute bacterial sinusitis.• acute otitis media.• acute exacerbations of chronic bronchitis.• cystitis.• pyelonephritis.• uncomplicated skin and soft tissue infections. •treatment of early lyme disease.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - coated tablets - sirolimus 1 mg - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.